chr19-11113415-T-C
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP3_StrongPP5
The ENST00000558518.6(LDLR):c.1324T>C(p.Tyr442His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y442C) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000558518.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.1324T>C | p.Tyr442His | missense_variant | 9/18 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LDLR | ENST00000558518.6 | c.1324T>C | p.Tyr442His | missense_variant | 9/18 | 1 | NM_000527.5 | ENSP00000454071 | P3 |
Frequencies
GnomAD3 genomes Cov.: 29
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 29
ClinVar
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:2
Pathogenic, no assertion criteria provided | research | Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum | - | - - |
Likely pathogenic, criteria provided, single submitter | literature only | LDLR-LOVD, British Heart Foundation | Mar 25, 2016 | - - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 07, 2021 | The p.Y442H variant (also known as c.1324T>C), located in coding exon 9 of the LDLR gene, results from a T to C substitution at nucleotide position 1324. The tyrosine at codon 442 is replaced by histidine, an amino acid with similar properties, and is located in the YWTD motif of the LDLR type B repeat region. This variant, also referred to as p.Y421H, has been detected in individuals with definite or suspected familial hypercholesterolemia (FH); however, details were limited (Widhalm K et al. J Inherit Metab Dis, 2007 Apr;30:239-47; Ambry internal data). This variant has also been detected in a sudden death victim with atherosclerosis, ventricular dilation, and myocyte degeneration in the setting of a history of reported anabolic steroid abuse (Larsen MK et al. J Forensic Sci, 2012 May;57:658-62; Larsen MK et al. Forensic Sci Int, 2012 Jun;219:33-8). Based on internal structural analysis, this variant is predicted to be structurally disruptive to the LDLR type B repeat (Jeon H et al. Nat Struct Biol. 2001 Jun;8(6):499-504; Lo Surdo P et al. EMBO Rep. 2011 Dec;12(12):1300-5). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Familial hypercholesterolemia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 15, 2020 | Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Tyr442 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been observed in individuals with LDLR-related conditions (PMID: 15576851, 11857755), which suggests that this may be a clinically significant amino acid residue. This variant has been observed in individual(s) with clinical features of familial hypercholesterolemia or premature atherosclerosis (PMID: 17347910, 22220933). This variant is also known as Y421H in the literature. ClinVar contains an entry for this variant (Variation ID: 251786). This variant is not present in population databases (ExAC no frequency). This sequence change replaces tyrosine with histidine at codon 442 of the LDLR protein (p.Tyr442His). The tyrosine residue is highly conserved and there is a moderate physicochemical difference between tyrosine and histidine. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at